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assessing quality, using common endpoints at 6 months,
1, and 2 years, ﬁve trials on orlistat (120mg TID) and six
on sibutramine (10mg QD) were selected. Pooled esti-
mates of weighted mean difference (between placebo and
drug) in proportion of patients losing 10% or more of
body weight (the primary outcome) were derived. Life-
time health and economic beneﬁts of sustained 10%
weight loss for adults aged 35–64 years with mild (BMI 
27.5kg/m2), moderate (BMI 32.5kg/m2) and severe (BMI
37.5kg/m2) obesity from a recently published cost-of-
obesity model (Am J Public Health, 1999,89:1536) of 
the relationship between BMI, risks, and cost of ﬁve
obesity-related diseases (hypertension, hypercholes-
terolemia, diabetes, coronary heart disease, stroke) were
used. Using direct costs, CBA was performed with
weighted average savings (transformed to year 2001 US$)
by age, BMI, and proportion losing 10% or more of body
weight. Sensitivity analysis by varying the proportion of
patients sustaining 10% weight loss (+/-20%) and dis-
count rate was done.
RESULTS: Beneﬁt-cost ratios of orlistat and sibutramine
were less than one for the base-case analysis at 6 months,
1 year and 2 years. Best/worst-case beneﬁt-cost ratio (via
sensitivity analysis) of orlistat remained less than one,
while that of sibutramine was 1.8/1.2 at 1 year.
CONCLUSIONS: Unless the proportion of patients 
sustaining 10% weight-loss increases, neither orlistat nor
sibutramine would prove cost-beneﬁcial in formulary
coverage decisions.
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OBJECTIVE: While a “class effect” is often attributed to
ACE-Inhibitor (ACE-I) therapy in hypertension, phar-
macokinetic and pharmacodynamic differences exist
between agents for endpoints such as trough :peak ratio
and lipophilicity. Agents with these clinical advantages
may enable patients to more consistently achieve and
maintain low blood pressure (BP) than agents with lower
trough :peak ratios and poorer lipophilicity. This study
assessed the economic implications of these clinical 
beneﬁts in the management of hypertension. 
METHODS: A literature-based decision model was
developed to project the relative costs and effectiveness
over one year of four commonly prescribed ACE-Is
(benazepril, lisinopril, ramipril and quinapril) versus
trandolapril from the perspective of a typical managed
care plan (MCO) with 100,000 members, of whom 1,700
were projected to take ACE-Is for hypertension. Therapy
effectiveness was measured as the proportion of patients
achieving BP control. Controlled patients were assumed
to incur substantially lower non-drug costs ($599–
$1,048) than uncontrolled patients ($4,449–$17,751).
Drug costs reﬂected the price and actual dose taken based
on national prescription data. In the most conservative
scenario, all therapies were assumed to result in identical
levels of BP control (59%). In the least conservative sce-
nario, it was assumed that patients taking therapies with
either poorer lipophilicity or lower trough: peak ratios
would be less frequently controlled (38%).
RESULTS: Trandolapril saved between $48,000 to
$235,000 compared to other ACE-Is in the most conser-
vative scenario. In the least conservative scenario, the cost
of therapies with lower BP control increased signiﬁcantly
and exceeded that of trandolapril by $1.8 to $2.0 million.
CONCLUSIONS: In both scenarios, trandolapril saved
costs relative to comparator ACE-I therapies. These
savings were driven by trandolapril’s lower price and 
the clinical beneﬁts anticipated to result from its lower
trough :peak ratio and better lipophilicity. These beneﬁts
include more consistent BP control and reduced need for
multiple dosing.
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This study presents ﬁrst attempt in Russia to assess will-
ingness to pay for medication treatment.
OBJECTIVE: To obtain monetary valuation of beneﬁts
concerned with avoiding amputation in case of critical
limb ischemia in Russia. 
METHODS: 191 physicians and 137 health care man-
agers ﬁlled in the questionnaire about their willingness 
to pay for medication treatment for critical limb ischemia
with prostaglandin E1 if amputation rate decreases to
12% in comparison with 48% in present common prac-
tice. The probability of amputation was extracted from 
a retrospective analysis of the outcomes of managing 105
patients with critical limb ischemia in common practice
and a published follow-up study of 752 patients treated
with prostaglandin E1 at Moscow surgery center. The
respondents had to assess their maximum out-of-pocket
expenses and maximum possible expenses for national
health care system (NHCS). 
RESULTS: 22.8% of respondents could not give a mon-
etary value for the hypothetical situation. Median value
for out-of-pocket expenses was 30,000 roubles (about
1,000 USD$); the range 1,500–435,000 roubles for 
physicians and 15,000 roubles (500 USD); the range of
500–175,000 roubles for health care managers. Accord-
ing to physicians opinion, payment from the NHCS
should be 70 ± 30% of the named sum. Health care man-
agers answered that NHCS should cover about 80 ± 27%
of the expenses.
CONCLUSION: First experience of assessing willingness
to pay showed that health care managers in Russia are
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valuing beneﬁts concerned with avoiding amputation
twice less than physicians. Anyway the price of
prostagladin E1 is about 350 USD for a period of treat-
ment that is much less than the median sum of money
named by both groups of respondents.
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Hypothermia resulting from invasive surgical procedures
can increase blood and ﬂuid loss and complicate the 
post-operative course of recovery. Therefore, hypother-
mia can be quite costly to treat. The Arctic SunTM Model
100 is new a non-invasive perioperative warming device,
which controls body temperature through single use
Arctic Sun Energy Transfer PadsTM regulated by a control
module.
OBJECTIVE: To compare the initial surgical and inten-
sive care unit (ICU) outcomes and costs resulting from
use of the Arctic Sun vs. standard care of temperature
management in patients undergoing off-pump coronary
artery bypass (OPCAB) surgery. 
METHODS: Data from two clinical studies conducted at
a major university were combined with other published
data to compare surgical outcomes and treatment costs
to the hospital associated with patient re-warming
methods.
RESULTS: Preliminary ﬁndings in OPCAB procedures
indicate post-operative hypothermia incidence is lower
for patients using the Arctic SunTM Model 100 (5% n =
58) compared to patients warmed using the standard
warming methods (48%, n = 48). An additional cost of
over $338.00 per patient for blood products and ﬂuids
received by patients was incurred for the standard care
population compared to the Arctic SunTM population.
Compared to normothermic patients, patients who are
hypothermic have an average increased hospital stay of
5.8 days ($2,616.96), and an average increased ICU time
of 4.2 hours ($236.88). Combining these costs with the
costs to treat infections, morbid cardiac events, and addi-
tional lab work, the total additional costs for complica-
tions due to hypothermia can easily exceed $8,270 per
patient. 
CONCLUSION: The Arctic SunTM is an effective tem-
perature management device for OPCAB patients. Com-
bining the Arctic SunTM clinical data with published
economic data suggests that the Arctic SunTM for tem-
perature management in OPCAB procedures could save
over $33,800 in blood product costs and over $355,000
in complication costs per 100 patients.
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OBJECTIVE: Patients on long-term anticoagulation
requiring interruption of therapy for a surgical procedure
historically have been hospitalized to receive “bridging
therapy” with continuous infusion intravenous unfrac-
tionated heparin (UFH). Recently, low-molecular weight
heparins such as enoxaparin have been reported to have
comparable safety and efﬁcacy in this indication, and can
be administered on an outpatient basis. The objective of
this study was to compare the costs of bridging therapy
with enoxaparin versus UFH in this patient population. 
METHODS: We conducted a cost-minimization analysis
of bridging therapy from the perspective of a third-party
health insurer. Patient treatment protocols were set forth
to reﬂect current clinical practice. Bridging therapy was
assumed to take place over an eight-day period, reﬂect-
ing three preoperative days, one day of surgery, and four
postoperative days. Three alternative bridging strategies
were considered: (1) UFH 30,000 units/day administered
in hospital; (2) enoxaparin 1.0mg/kg self-administered
twice-daily by the patient at home; and (3) enoxaparin
1.5mg/kg administered once-daily in the patient’s home
by a visiting nurse. Various secondary sources were 
used to estimate the costs of drug acquisition, ancillary
supplies, provider services, and hospitalization. Analyses
were performed for day surgery, surgery requiring
overnight stay, and surgery requiring a stay of 4+ days.
RESULTS: Bridging therapy with UFH in hospital costs
$4,397 per patient for day surgery, $3,818 for procedures
requiring an overnight stay, and $2,080 for procedures
requiring a stay of 4+ days (2001 US$). Corresponding
cost estimates for patient-administered enoxaparin are
$663, $673, and $743. Cost estimates for nurse-
administered enoxaparin are $990, $935, and $771,
respectively.
CONCLUSIONS: Bridging therapy with enoxaparin 
at home whether patient-administered or nurse-
administered is substantially less costly than bridging
with UFH in hospital. The magnitude of cost savings is
highest for day surgery and lowest for surgeries requiring
a prolonged recovery in hospital.
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